Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
Mariano Provencio PullaRoberto Serna-BlascoErnest NadalAmelia InsaRosario Garcia CampeloJoaquín Casal RubioManuel DómineMargarita MajemDelvys Rodriguez AbreuAlex Martinez-MartiJavier De Castro CarpeñoManuel CoboGuillermo López VivancoEdel Del BarcoReyes Bernabé CaroNuria ViñolasIsidoro Barneto ArandaSantiago ViteriEva PereiraJuan-Antonio VargasVirginia CalvoJavier Martín-LópezFrancisco García-GarcíaMarta CasarrubiosFernando F FrancoEstela Sánchez-HerreroBartomeu MassutiAlberto Cruz-BermúdezAtocha RomeroPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year OS. ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.